Member Info for Knotagain

Mcsquares, that someone was me and it's called sarcasm.

Your cheeky bid of £1.65 is way off the mark, try moving the decimal point between the 6 and the 5.

Don't get your hopes up Timster, they'll still be playing hard to get in 2035.

The first six months of the year saw a number of managerial and operational changes, while its financial position remains in line with the Board’s expectations.

Management Comments

New Chairman Shaun Chilton stated that:

“Over the four months since Chris Coughlin’s and my appointments, we have made significant progress on key strategic priorities.

Alongside the Board and wider team, we have carried out a detailed review of all the Group’s operations and financials with a focus on prioritizing further investments in therapeutics, including the acceleration of the AVA6000 clinical trial enrolment.  

We are very encouraged by the potential of the innovative medicines in the Avacta pipeline which we plan to present at our live R&D Spotlight in October focusing on the Next Generation of the pre|CISION™ platform.

We have commenced a process to divest the Diagnostics Division and have started to receive indicative offers.

Our longer-term financing strategy is being formulated and includes a potential dual listing of the Company on NASDAQ, which the Board sees as a key strategic option for the Company.”

Avacta aims to leverage its proprietary pre|CISION™ platform to develop innovative oncology therapies that make a significant difference to cancer patients’ treatment experience and outcomes.

The pre|CISION™ platform has the potential to enable patients to achieve improved outcomes with fewer side effects by leveraging the tumor specific enzyme Fibroblast Activation Protein (FAP) to protect normal tissues from toxic drugs.

The group is poised to move into the next stage of development, implementing these findings of this drug release mechanism across our innovative pipeline.

New CEO Christina Coughlin, MD, PhD, stated that:

“We are seeing notably positive progress on our drug development candidate AVA6000 with the completion of the Phase 1a trial with no maximum tolerated dose and opening of the RDE expansion. 

This novel peptide drug conjugate continues to demonstrate a highly favourable tolerability profile and robust preliminary signs of efficacy, with several durable responses, as it moves through clinical development.

The AVA6000 data in the clinic has led to a growing confidence in the pre|CISION™platform and its potential for patients.

Our next generation programs will leverage the pre|CISION™ platform as a foundation for other tumor-specific warhead delivery systems.

This platform will underpin our wider clinical strategy and our ambition of bringing these novel cancer medicines closer to patients and delivering value for shareholders.”

Analyst Views

At Trinity Delta, its analysts Lala Gregorek and Philippa Gardner consider that Avacta is transitioning into a developer of innovative highly targeted specialist oncology products.

They state that once the Diagnostics division has been divested, Avacta wi

Logo

Shares

Updated: 03/10/2024

Avacta Group – Exploring NASDAQ Dual-Listing And Divesting Its Diagnostics Division, Analyst Has 188p Valuation, Shares Now 45.5p

Mark Watson-Mitchell

By

Mark Watson-Mitchell

03/10/2024

On Wednesday 30th October, Avacta Group (LON:AVCT), the cancer treatments and diagnostics life sciences business, will be presenting a live Research & Development Spotlight entitled Next Generation of pre|CISION Medicines.

It is expected that there will be keen investor interest to hear what the group has to say about its pre|CISION platform.

- Advertisement -

The Business

Subscribe to our newsletter

Avacta Group is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics.

It has two main segments: a clinical stage oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs, and a diagnostics division focused on supporting healthcare professionals.

Avacta Therapeutics: which is the clinical stage oncology biotech division that is harnessing the proprietary pre|CISION platform technology to develop novel, highly targeted cancer drugs.

- Advertisement -

The pre|CISION™ platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues.

Avacta Diagnostics: which focuses on supporting healthcare professionals and broadening access to diagnostics, has two business units – Launch Diagnostics and Coris Bioconcept.

Launch Diagnostics is a well-established sales channels in the professional, centralised hospital laboratory testing market in the UK and France.

Coris, based in Gembloux, Belgium, develops, manufactures and markets rapid diagnostic test kits, mainly lateral flow tests, for use by healthcare professionals.

In the highly competitive diagnostics market, Avacta’s proprietary Affimer® platform has the potential to provide differentiated immunodiagnostic products to gain competitive advantage and grow market share.

This Week’s Interim Results

Last Monday morning the group reported its Interim Results for the six months to end-June, showing much in line with expectations, with revenues off slightly at £11.3m (£11.9m) and running at a first-half loss of £12.5m (£11.5m).

The Diagnostics division revenues advanced to £11.2m (£9.9m), however, it must be noted that the company has started the process to divest this side of the business, in order to maximise value for shareholders, while ensuring its focus as a therapeutics-focused company and support its appeal to specialist international investors.

After the £31.1m cash raise in March this year, the group ended the period with £32.5m cash and cash equivalents, against £26.6m at the same time last year.

The first six months of the year saw a number of managerial and opera

Touk, ' so you are the self appointed voice of the BB"

Touk - 174 post's in the last 30 days.

seethreeIPO - 14 post's in the last 30 days.

You really couldn't make this xxxx up.

The Yorkshire post are asking more than the cost of an Avacta share just to read the article.

Don't think I'll bother

If only you became a footnote in history.

Avacta have been excellent at talking about the science and I'm definitely sold on it. But until they start talking about commercialisation the SP will remain a play thing for traders and shooters.

A licence deal or buyout are the only things the market wants to hear about.

Come on CC, let's do this.

Thornogson, 94 negative posts on Avacta over the last 30 days.

I think the trolls are getting a bit desperate.

LG Chem exec links bio industry success to K-content, stresses open innovation

기자명 Kim Chan-hyuk Published 2024.09.05 11:28

“The success of K-entertainment businesses like the Netflix series 'Squid Game' is an example of unpredictable success, and the bio industry has something in common with the drama as it is an intellectual property- and uncertainty-based industry. Industries based on intellectual property rights inherently carry very high risks. However, when they succeed, the rewards can be tremendous.”

Son Jee-woong, president of LG Chem’s Life Science Business, said so in the opening ceremony of the “Global Bio Conference (GBC),” which opened at the Grand InterContinental Seoul Parnas Hotel on Wednesday, emphasizing the importance of building an innovation ecosystem.

Son Ji Woong, president of LG Chem's Life Science Business, gives a presentation during the Global Bio Conference (GBC) at the Grand InterContinental Seoul Parnas Hotel on Wednesday. (KBR photo)

Son Ji Woong, president of LG Chem's Life Science Business, gives a presentation during the Global Bio Conference (GBC) at the Grand InterContinental Seoul Parnas Hotel on Wednesday. (KBR photo)

Explaining the similarities between the biopharmaceutical and the K-entertainment industries, Son noted that the bio industry has much to learn from the success of K-content, such as “Squid Game.” He also cited various partnerships and collaborations as one of the success factors of K-content, stressing that the biopharmaceutical industry can grow through such collaboration and innovation.

“The bio industry requires a development cycle of more than 10 years and huge investment costs, and it is essential to collaborate with various fields and make steady investments to create innovative medicines. The possibility of failure is very high, so how to ‘manage failure is key,’” he said, emphasizing the need to build an innovation ecosystem to solve this problem.

“The bio industry is considered one of the top 10 growth industries in the future and is expected to grow at an average annual rate of more than 9 percent,” Son said, explaining that this growth is driven by the increasing demand for healthcare due to the aging population and advances in science and technology. “New treatment options are constantly emerging, and investments in the bio sector are increasing rapidly,” he said, reiterating the importance of the bio industry.

Son also emphasized the importance of open innovation and introduced various global partnerships that LG Chem is pursuing. In collaboration with Nasdaq-listed Cue Biopharma, LG Chem has introduced three new immuno-oncology drug projects. It also works with British biotech Avacta to codevelop protein therapeutics for cancer and immune diseases.

Son explained that such an open innovation strategy is a crucial driving force

Says Thorn, 2,772 post's since January 2023.

Give us a break.

It's fantastic that AVA6000 has been mentioned by Cancer Research UK. Thanks for posting.

Ice, nothing wrong with taking the bait now and again, people new to the board need to know who the trolls are.

Touk, you're always fed up and always will be fed up and we'll always be fed up with you.

ManUp, we also have a few resident trolls that do the opposite of ramping.

It would be for me, I've been on this AIM roller coaster for far too long.

Ice, I meant could as in should.

Otherwise should have been it.

GSA could have started buying back in the low 50s only a couple of days ago, but decided against otherwise.

I really do hope they get absolutely hammered.

Tesla, Game Stop and Piggly Wiggly come to mind.

GLA.

Nicolas870, If you were diagnosed with cancer tomorrow I suspect you would have a completely different view of Avacta as an investment.